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Abstract Inflammation is a predominant aspect of neu-
rodegenerative diseases, manifested by glia activation and
expression of pro-inflammatory mediators. Studies on
animal models of Parkinson’s disease (PD) suggest that
sustained neuroinflammation exacerbates degeneration of
the dopaminergic (DA) nigro-striatal pathway. Therefore,
insights into the inflammatory mechanisms of PD may help
the development of novel therapeutic strategies against
this disease. As extracellular matrix metalloproteinases
(MMPs) could be major players in the progression of
Parkinsonism, we investigated, in the substantia nigra and
striatum of mice acutely injected with 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), changes in mRNA
expression, protein levels, and cell localization of MMP-9.
This protease is mainly neuronal, but early after MPTP
injection its mRNA and protein levels, as well as the
number of MMP-9-expressing microglia and astrocytes,
increase concomitantly to a prominent inflammation.
Neuroinflammation and MMP-9? glia begin to decline
within 2 weeks, although protein levels remain higher than
control, in association with a partial recovery of DA nigro-
striatal circuit. Comparable quantitative studies on MMP-9
knock-out mice, show a significant decrease in both glia
activation and loss of DA neurons and fibers, with respect
to wild-type. Moreover, in a parallel study on chronically
MPTP-injected macaques, we observed that perpetuation
of inflammation and high levels of MMP-9 are associated
to DA neuron loss. Our data suggest that MMP-9 released
by injured neurons favors glia activation; glial cells in turn
reinforce their reactive state via autocrine MMP-9 release,
contributing to nigro-striatal pathway degeneration. Spe-
cific modulation of MMP-9 activity may, therefore, be a
strategy to ameliorate harmful inflammatory outcomes in
Parkinsonism.
Keywords Metalloproteinases  Neuroinflammation 
Parkinson’s disease  Neurodegeneration
Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by progressive loss of dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNpc)
(Hirsh et al. 1998; Braak et al. 2003, 2006). Idiopathic PD
affects mainly the elderly, but it can also develop in young
people, where a genetic component may play a prominent
role (Houlden and Singleton 2012). The etiology of this
disease remains to be elucidated; however, as PD is char-
acterized by a prominent inflammatory reaction, which
becomes chronic along the years, neuroinflammation may
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play a role in exacerbation (Hirsch and Hunot 2009; Tan-
sey and Goldberg 2010), or even promotion (Whitton
2010), of the disease. Post-mortem analysis (McGeer et al.
1988; Hirsh et al. 1998; Ouchi et al. 2005, 2009; Braak
et al. 2007) and in vivo imaging (Ouchi et al. 2005, 2009;
Gerard et al. 2006) of PD patient brains showed activation
of microglia, astrogliosis and infiltration of peripheral
immune cells in the SNpc and other regions. These features
were also observed in the brain of young drug addicts, who
made use of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (Langston et al. 1983), and in
animal models of Parkinsonism, such as MPTP-injected
mice and monkeys (Barnum and Tansey 2010; Walsh et al.
2011). Increased levels of pro-inflammatory cytokines in
both SN (Hunot et al. 1996; Hirsh et al. 1998; Barcia et al.
2005, 2011) and cerebrospinal fluid (Nagatsu et al. 2000;
Pott Godoy et al. 2008) of PD patients and animal models
have also been described. The complexity of the immune
response, however, does not allow to unequivocally
establish whether reactive ‘‘neuroglia’’ contributes to DA
neuron death. Anti-inflammatory therapies are used in the
treatment of a number of neurodegenerative disorders,
including PD (Whitton 2010; L’Episcopo et al. 2010);
however, from a drug-development perspective, a complete
understanding of the factors and mechanisms ruling the
onset and progression of disease-specific inflammatory
processes is most needed. An intriguing idea is that glial
cells may play important and diverse roles during the
progression of the disease, a critical moment being the
switch from acute to chronic inflammation.
Matrix metalloproteinases (MMPs) are extracellular
proteases that finely modulate several physiological and
pathological/inflammatory processes (Parks et al. 2004;
Page-McCaw et al. 2007; Candelario-Jalil et al. 2009;
Wright and Harding 2009). MMP-2 and -9 are highly
expressed in the brain in physiological conditions, and
MMP-9 and -3 are significantly up-regulated in several
brain pathologies, including PD (Lorenzl et al. 2002, Kim
et al. 2007, 2011; Choi et al. 2008), highlighting them as
possible therapeutic targets (Leonardo and Pennypacker
2009). Specific MMP inhibitors have been developed;
however, indiscriminate block of this enzymatic activity
is a dangerous ground, since MMPs play different roles
depending on the type of pathology and time of
activation.
In this study, we investigated changes in MMP-9
expression and localization in the MPTP mouse and
monkey models of Parkinsonism. Our results indicate
that: (1) MMP-9 is important for inflammatory glia acti-
vation, which in turn exacerbates DA neuron loss; (2) at
later stages, when neuroinflammation subsides, MMP-9
may contribute to partial recovery of the nigro-striatal
pathway.
Materials and methods
All studies were carried out in accordance with the
guidelines promulgated in the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH
Guide, revised 1996), in the European Convention for the
protection of Vertebrate Animals used for Experimental
and other scientific purposes of the Council of Europe (no
123, June 15th, 2006), and in accordance with The Code of
Ethics of the EU Directive 2010/63/EU. All efforts were
made to minimize animal suffering, to reduce the number
of animals used, and to utilize alternatives to in vivo
techniques. The experimental procedures and protocols
were approved by the Ethical Committee for Animal
Research of the University of Murcia and of the Italian
Ministry of Public Health.
MPTP treatment
Mice
We used 3-month-old male C57BL/6J mice, B6.FVB(Cg)-
Mmp9tm1Tvu/J mice and their matching wild-type (WT)
mice (The Jackson Laboratory, Bar Harbor, MA, USA).
Mice were housed in a separate room, at 21 C, under a
12 h (h) day-night cycle and with food and water ad libi-
tum. Acute MPTP treatment was performed according to
established protocols (Jackson-Lewis et al. 1995). Briefly,
mice received four intra-peritoneal (i.p.) injections of
20 mg/kg of MPTP HCl (Sigma-Aldrich, St. Louis, MO,
USA) dissolved in 0.9 % NaCl at 2 h intervals. We always
used freshly diluted MPTP and adopted special animal care
(i.e. warm room temperature and cages provided with
cotton wool) to minimize mice loss after treatment. Only
five mice over the total used (see details below) died after
MPTP injection. Control mice received equivalent injec-
tions of saline. The number of mice used was: for molec-
ular biology and biochemical studies, 8 mice/experimental
group and type of analysis, for a total of 112 mice (56 mice
each); for confocal microscope analysis, 4 mice/experi-
mental group, for a total of 20 mice; for immunohisto-
chemistry, 5 WT mice/experimental group and 8 MMP-9
KO mice/experimental group, for a total of 15 WT and 24
MMP-9 KO mice, respectively. Mice were killed at
established time points (see specific paragraphs) and brains
removed and processed for the different types of analyses.
Macaques
Brain sections were derived from a colony of chronic
parkinsonian macaques (Macaca fascicularis) previously
established and studied at the Primate Unit of the Univer-
sity of Murcia, and were properly stored. Samples were
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obtained from six young adult macaques, four of which had
been treated weekly with low intravenous doses of MPTP
(0.3 mg/kg) until stable Parkinsonism was established
(Herrero et al. 1993; Barcia et al. 2003). This varied,
depending on individual susceptibility to the toxin. Pro-
gressive motor alterations were assessed using a rating
scale ranging from 0 to 25 (Herrero et al. 1993) (Table 1).
Parkinsonian macaques were killed 2 years after the last
MPTP administration. Monkeys not treated with MPTP
were used as controls. For this study, three controls and 5
parkinsonian macaques were used.
Real-Time reverse transcriptase-polymerase chain
reaction
mRNA levels of MMP-9 were assessed in the brain of
control and MPTP-treated C57BL/6J mice by Real Time
Reverse transcriptase-Polymerase Chain Reaction (RT-
PCR). Animals were deeply anesthetized with isoflurane
(Merial, Harlow, UK) and killed by decapitation at dif-
ferent time points after the last MPTP injection: 1, 24, 48,
72 h, 1 week and 2 weeks. Brains were rapidly removed,
frozen in liquid nitrogen-cooled isopentane, and stored at
-80 C until use. Frozen brains were cut in 1 mm-thick
coronal sections on a matrix for brain slicing (AgnTho’s,
Lidingo¨, Sweden), and dorsal striatum and SN were
removed by excision with a thin needle and a punching
device of 0.75 mm of internal diameter (AgnTho’s),
respectively. Samples were rapidly homogenized for RNA
extraction.
RNA extraction, quantification and reverse transcription
Total RNA was isolated from SN and striatum of control
and MPTP-treated C57BL/6J mice using the RNeasy Micro
kit (Qiagen, Milan, Italy) according to the manufacturer’s
instructions. RNA was purified from genomic DNA using
the DNA-free kit (Ambion, Austin, TX, USA), and
quantity and purity were assessed by the Nanodrop ND-
1000 spectrophotometer at 260 nm. RNA integrity was
assessed by electrophoresis on ethidium bromide-stained
1 % agarose-formaldehyde gels. RNA was reverse-tran-
scribed as previously described (Del Signore et al. 2006)
using the cDNA synthesis kit (Bioline, London, UK).
cDNA samples were stored at -20 C until use.
Real-time RT-PCR
2.5 ll of cDNA was amplified by real-time RT-PCR in
25 ll of a reaction mixture containing 12.5 ll of 29 SYBR
Green JumpStart Taq ReadyMix (Sigma-Aldrich), 0.25 ll
of Internal Reference Dye and 3 ll of each specific primer
(5 lM final concentration forward ? reverse) (Sigma-
Aldrich), using an iCycler iQ Real-Time Detection System
(Bio-Rad, Milan, Italy). Each sample was amplified in
duplicate for 30–35 cycles. Amplicons were detected after
each elongation step and analyzed using the iCycler iQ
software (Bio-Rad). A melting curve was obtained after
completion of the cycles to verify the presence of a single
amplified product. Relative quantification was carried out
with the 2-DDCt method (Livak and Schmittgen 2001),
using the abundance of hypoxanthinephospho-ribosyl-
transferase (HPRT) as endogenous house-keeping control.
The specificity of each pair of primers was confirmed by
comparing to a negative control with water. Primers used
were the following:
MMP-9 F, 50-GGCGTGTCTGGAGATTCG-30, R, 50-
ATGGCAGAAATAGGCTTTGTC-30;
HPRT F, 50-AGTCCCAGCGTCGTGATTAG-30, R, 50-
CCATCTCCTTCATGACATCTCG-30
Western immunoblot
Primary antibodies
Rabbit polyclonal antibodies against MMP-9 (1:2,000) and
tyrosine hydroxylase (TH) (1:1,000) were from Chemicon
(Temecula, CA, USA). Mouse monoclonal antibody
against glyceraldehyde phosphate dehydrogenase (GAP-
DH, 1:5,000) was from Abcam (Cambridge, UK).
Preparation of tissue extracts, electrophoresis
and immunoblotting
Time periods of MPTP treatment and tissue preparation
from control and MPTP-treated C57BL/6J mice were as
described for real-time RT-PCR. Tissues were homoge-
nized with a ground-glass micro-homogenizer in ice-cold
RIPA buffer (50 mM Tris/HCl pH 7.6, 150 mM NaCl,
1 mM EDTA, 1 % SDS, 1 % Triton X-100, 19 of a
cocktail of inhibitors, 1 mM PMSF, 0.2 mM Na3VO4 and
Table 1 Motor score of Parkinsonism evaluated for each monkey,
cumulative dose of MPTP received and time of survival after the last
MPTP administration
Monkey Sex Motor score MPTP (mg/Kg) Years after MPTP
C1 M 0.0 0 –
C2 M 0.0 0 –
C3 F 0.0 0 –
P1 M 3.5 1.8 2
P2 F 4.2 0.9 2
P3 M 5.0 1.8 2
P4 F 9.2 0.9 2
C control, P Parkinsonian, M male, F female
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1 mM NaF). After centrifugation (15,0009g, 15 min at
4 C), a measured volume of supernatant was analyzed to
determine total protein concentration using the Micro BCA
kit (Pierce, Rockford, IL, USA). Other aliquots of the
supernatant were diluted with 49 reducing loading buffer
(200 mM Tris/HCl pH 6.8, 4 % SDS, 30 % glycerol, 4 %
b-mercaptoethanol, 4 % blue bromophenol), boiled for
3 min at 100 C, and stored at -20 C until use.
Eighty micrograms of proteins of each sample were
separated on 8 % SDS–polyacrylamide gels. Loading of
such a high amount of proteins was necessary to obtain a
proper densitometric signal, as the levels of MMP-9 in SN
and striatum from a single mouse are too low with respect
to total protein content. Molecular mass standard (Color-
Burst, Sigma-Aldrich), containing precisely sized
recombinant proteins of 210, 90, 65, 40, 30, 20, 13 and
8 kDa, along with human recombinant gelatinases MMP-9
and MMP-2 (used as positive controls), were loaded on
separate lanes next to the specimen homogenates. Gels
were run at a constant 200 V, proteins transferred over-
night onto a nitrocellulose membrane (transfer buffer:
50 mM Tris/HCl, 380 mM glycine, 0.1 % SDS and 20 %
methanol) and correct electrophoretic migration and uni-
form protein loading were verified by Ponceau S staining
(Biorad). Non-specific binding sites were blocked in 5 %
dry milk (DM) (Carnation instant no-fat milk, Nestle´,
USA), diluted in 19 TBST (20 mM Tris/HCl pH 7.5,
500 mM NaCl, 0.05 % Tween-20) (2 h at RT). Membranes
were successively incubated (overnight at 4 C) with the
primary antibodies (diluted in 3 % BSA, 0.05 % NaN3, 19
TBST) and then (1 h at RT) with the appropriate horse-
radish peroxidase (HRP)-conjugated secondary antibody
(Promega, Madison, WI, USA): goat anti-rabbit IgG or
goat anti-mouse IgG, diluted 1:10,000 and 1:15,000,
respectively, in 2.5 % dry milk, 19 TBST. Antibody
binding sites were revealed using an enhanced chemilu-
minescence (ECL) kit (Pierce, Rockford, IL, USA) and
exposing membranes to the Hyperfilm ECL (GE Health-
care, Waukescha, WI, USA). Densitometric analysis of the
immunopositve bands was performed using the Image-
Quant 5.2 software (GE Healthcare). The optical density
(OD) of each band, expressed as arbitrary gray units, was
normalized against the OD of the GAPDH-positive band in
the same lane, used as the internal reference protein.
Densitometric values were expressed as the ratio of OD
between MPTP and control mice.
In situ zymography
Gelatinolytic activity (MMP-9 and MMP-2) in SNpc and
striatum of control and MPTP-treated (72 h) C57BL/6J
mice was evaluated by in situ zymography on frozen brain
sections. Animals were anesthetized with isoflurane and
killed by decapitation, brains were rapidly removed, frozen
on dry-ice and stored at -80 C until use. Coronal serial
sections (10 lm-thick) were cut at a cryostat, mounted on
Super Frost Ultra Plus glass slides (Menzel-Gla¨ser,
Braunschweig, Germany) and incubated overnight at 37 C
in a gelatinase activation buffer composed by 50 mM Tris/
HCl (pH 7.6), 150 mM NaCl, 5 mM CaCl2, 0.2 mM NaN3
e 50 lg/ml of DQTM Gelatin from Pig Skin Fluorescein-
Conjugated (Molecular Probes, Eugene, OR, USA). Neg-
ative controls were obtained by adding 20 mM EDTA to
the activation buffer. Before being coverslipped with Pro-
long Gold anti-fade reagent (Invitrogen), sections were
post-fixed (30 min at RT) with 4 % formalin in phosphate
buffered saline (PBS) and nuclei counterstained with di-
amidino-2-phenylindole (DAPI) (1:1,000, Invitrogen).
Sites of proteolytic activities, visible as a fluorescent
emission consequent to gelatin enzymatic cleavage by
MMPs, were observed with a Zeiss Axioplan 2 microscope.
Immunohistochemistry, immunofluorescence
and confocal analysis
Primary antibodies
Sheep anti-TH (1:1,000), mouse anti-NeuN (1:500), mouse
anti-glial fibrillary acid protein (GFAP, 1:500) and rabbit
anti-MMP-9 (1:1,000) were from Chemicon. Rabbit anti-
Iba-1 (1:500) was from Wako (Chuo-Ku, Osaka, Japan).
Animal treatment
Mice C57BL/6J mice, B6.FVB(Cg)-Mmp9tm1Tvu/J mice,
and their matching WT mice were deeply anesthetized with
an i.p. injection of ketamine (50 mg/kg body weight) and
xylazine (50 mg/kg body weight), and perfused transcar-
dially with an oxygenated Ringer solution (pH 7.3), fol-
lowed by 4 % freshly depolymerized paraformaldehyde
(PFA) in 0.1 M phosphate buffer (PB) (pH 7.4). Brains
were removed and cryoprotected in 30 % sucrose, at 4 C,
until they sank. Free-floating coronal serial sections
(25 lm-thick) were cut at a cryostat and stored in cryo-
protectant (ethylene glycol: 0.2 M PB, pH 7.4 in a 1:1
proportion, with addition of 0.5 M sucrose) at -20 C until
use. Experimental groups and times after MPTP treatment
were the following: C57BL/6J (control, 24, 48, 72 h, 1 and
2 weeks after MPTP injection), B6.FVB(Cg)-Mmp9tm1Tvu/J
mice and their matching WT (control, 72 h and 2 weeks
after MPTP injection).
Macaques
Macaques were killed by a lethal injection of pentobarbital
after a pre-anesthesia with ketamine (8 mg/kg body
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weight). Brains were rapidly removed, fixed for 3 days in
4 % freshly depolymerized PFA in 0.1 M PB (pH 7.4) and
sectioned into coronal 40 lm-thick serial sections at a vi-
bratome (Barcia et al. 2004).
Immunofluorescence
Localization of MMP-9 by immunofluorescence was
enhanced using the Renaissance Tyramide Signal
Amplification (TSA)-biotin system kit (PerkinElmer),
according to the manufacturer’s instructions. After antigen
retrieval with citrate buffer (pH 6.0) (30 min at 65 C) and
quenching of the endogenous peroxidase activity, sections
were incubated (1 h at RT) in a TNB blocking buffer (0.1 M
Tris/HCl pH 7.5, 0.15 M NaCl, 0.5 % blocking reagent by
the manufacturer) and then (48 h at 4 C) with the rabbit
anti-MMP-9 antibody in combination with one of the other
primary antibodies (see above), diluted in TNB blocking
buffer. Amplification of the signal was obtained by incu-
bation (30 min at RT) with a biotinylated goat anti-rabbit
IgG secondary antibody (1:100, Vector Labs, Burlingame,
CA, USA), diluted in TNB blocking buffer, followed by
streptavidin–HRP conjugate (SA-HRP) (1:100, 30 min at
RT), and finally by a biotinyl tyramide working solution
(1:50 Biotinyl Tiramide Stock Solution diluted in 19
Amplification Diluent, 10 min at RT). Amplification was
blocked by rinsing the sections in TNT buffer, and anti-
body-antigen binding sites were revealed by a 30 min
incubation in the SA-Fluorescein conjugate (1:500 in TNB),
followed by the appropriate secondary antibody conjugated
with either Alexa Fluor 633 or Alexa Fluor 594 (1:1,000)
(Molecular Probes, Carlsbad, CA, USA). DAPI was used
for nuclear staining and sections were collected on glass
slides and coverslipped with the Prolong Gold reagent.
In mice, presence of MMP-9 in microglial cells was
ascertained by MMP-9 immunolabeling followed by a
staining with the widely used rhodamine-conjugated
tomato lectin, Griffonia Simplicifolia Lectin I (GSA)
(Vector Labs) diluted 1:100 (Pott Godoy et al. 2008).
Confocal analysis
Fluorescent specimens were viewed under a Leica
DMIRE2 confocal microscope (Leica Microsystems,
Wetzlar, Germany) with a 639 immersion-oil objective,
except for the MMP-9/tomato lectin localization, which
was analyzed at the Zeiss Axioplan 2 microscope, as
fluorescence faded rapidly under the laser beam. Acquired
images were analyzed with the Leica Confocal Software.
To avoid cross talk between the fluorophores, we carefully
adjusted the spectral ranges of detectors and scanned
images sequentially. Each section was scanned in 0.5 lm-
thick optical sections, the series range being determined by
setting the upper and the lower thresholds with the
Z/Y position for spatial image series setting. Images are
presented as a transparency of all layers merged together.
For further details see Barcia et al. (2008).
Immunohistochemistry
Endogenous peroxidase was inhibited (0.3 % H2O2 and
10 % methanol in PBS, for 15 min at RT) and then antigen
retrieval was performed as described above. After a pre-
permeabilization with 1 % Triton X-100, non-specific
antibody binding sites were blocked in 10 % normal horse
serum (NHS) in 0.1 M PBS (60 min at RT), and then slices
were incubated (48 h, at 4 C) with the anti-TH primary
antibody, diluted in 1 % NHS, 0.5 % Triton X-100, 0.1 %
NaN3 and PBS, followed by a biotinylated donkey anti-
sheep IgG (Jackson Immuno Research) (1:500, for 2 h),
and then the avidin–biotin-peroxidase complex (1:100,
30 min at RT) (ABC Vectastain Elite kit, Vector Labs).
Antibody binding sites were revealed by incubating the
sections in 0.25 mg/ml 3,30-diaminobenzidine (DAB) and
0.03 % H2O2 in PBS (10 min at RT). Negative controls
were obtained by omitting the primary antibodies. Sections
were mounted on gelatin-coated slides, dehydrated in a
series of ethyl alcohols and xylene, dried and permanently
coverslipped with Eukitt mounting medium (Kindler
GmbH, Freiburg, Germany).
Cresyl violet staining
Three random sections of the SN from each of the series
used for immunofluorescence of the MMP-9 knock-out
mice, and their matching WT mice, were stained with 1 %
cresyl violet for 2 min. Following dehydration in a series of
ethyl alcohol and xylene, sections were dried and perma-
nently coverslipped with Eukitt mounting medium. Stere-
ological quantification of the SNpc neurons was performed
as detailed in the next section.
Quantitative analysis
Immunohistochemistry
Number of TH? neurons in the SNpc and densitometric
value of TH immunolabeling in the striatum, as well as
number and area of GFAP? and Iba1? cells in both SNpc and
striatum of MMP-9 knock-out mice, revealed by the ABC-
DAB method, were estimated on three representative sec-
tions per each mouse brain series. Sections were viewed at a
Zeiss Axioplan 2 light microscope connected to a digital
camera (AxioCam HRc, Zeiss). Images of (SNpc) and stri-
atum were acquired by using a 209 and 1.259 objectives,
respectively. Density of immunopositive cells per area was
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expressed as the number of cells/mm2. TH immunolabeling
in the striatum was determined by the ImageJ software as
optical density (OD) values and was considered as an index
of the density of DA innervation. The area (lm2) occupied by
microglia and astrocytes (including both cell bodies and
processes), identified by specific labeling, was considered an
index of glial cell activation and was expressed as both total
and mean area occupied by immunopositive cells per pho-
tographic field. Mean cell area values were obtained by
dividing the total area covered by immunopositive cells for
their number. All data were generated using the ImageJ
software for image analysis. All quantifications were per-
formed blindly.
Immunofluorescence
Three representative sections of the SNpc and striatum of
each control and MPTP-treated mice, and 2 from each con-
trol and parkinsonian macaque striatum, were chosen and 3
random images were captured from both sides of sections.
Cells immunopositive for both MMP-9 and one of the
cell markers used were counted only when the area
of co-localization was detected in the majority of the 0.5 lm-
thick optical layers throughout the entire stack. The number
of single and double immunolabeled cells was quantified on
the best of the single 0.5 lm-thick optical sections, and
results were expressed as the number of immunopositive
cells/mm2. All quantifications were done blindly.
Statistical analysis
Data were analyzed using either the one-way ANOVA test
following the post hoc Dunnet’s test (adequate for multiple
comparisons against a single reference group) or the two-tail
Student’s t test (which compares two groups at a time). Dif-
ferences were considered statistically significant for p B 0.05.
Data were expressed as the mean ± standard error of the
mean (SEM). A Pearson coefficient was used for the corre-
lation analysis and its significance was determined using the
critical values of the Pearson coefficient table. Differences
were considered statistically significant for p B 0.05.
Results
MMP-9 mRNA and protein levels are modulated
in the nigro-striatal pathway by acute MPTP treatment
in mice
mRNA levels for MMP-9 (gelatinase B) were investigated
by real-time RT-PCR. Based on previous studies (Annese
et al. 2013), we explored a time window after the last
MPTP injection that spanned the entire period of DA
neuron degeneration and the partial recovery of those who
escaped death, along with the rising and subsiding of
neuroinflammatory events (Hirsch and Hunot 2009). MMP-
9 mRNA was significantly and consistently induced, in
both SN (Fig. 1a) and striatum (Fig. 1b), at different times
after acute MPTP administration. mRNA levels were up-
regulated (?1.8 folds, SN; ?2.2 folds, striatum) by 24 h
after the last MPTP injection, remaining significantly
higher than control in the following 48 h (?2.5 folds, SN)
(Fig. 1a) and 1 week (?1.2 folds, striatum) (Fig. 1b).
MMP-9 protein levels were investigated by Western
immunoblot in SN and striatum homogenates of control
and parkinsonian mice, killed at the same post-treatment
time as indicated above. The MMP-9 antibody revealed
two bands of about 97 kDa (pro-MMP-9) and 92 kDa
(active MMP-9) (Fig. 1c, SN; Fig. 1d, striatum). A human
recombinant MMP-9, used as positive control and loaded
on a separate lane in the same gels, appeared as a single
band corresponding to the active MMP-9, and migrated
slightly below its homologous in the mouse brain homog-
enates. Densitometric analysis of the immunopositive
bands revealed that, similar to mRNA, protein levels of
both pro- and active MMP-9 increased significantly by
24 h (Fig. 1c0, SN) and 1 h (Fig. 1d0, striatum) after MPTP
administration, remaining higher than control throughout
the post-treatment time considered. The apparent discrep-
ancy in the post-injection times, at which we observed the
main changes in MMP-9 mRNA and protein levels is a
common event, especially for MMPs since these proteins
are subjected to a prominent post-transcriptional control.
MMP-9 immunolocalization and quantitative analysis
in control and MPTP-treated mice
The persistent and significant increase in MMP-9 protein
levels in the SN and striatum of MPTP-treated mice involved
both the inactive pro-enzyme and its active form (post-trans-
lationally activated). However, this analysis did not allow the
identification of the type/s of cells expressing MMP-9 in
control conditions. Moreover, this preliminary observation
did not show changes in MMP-9 distribution after MPTP
treatment and, less than that, whether and how active MMP-9
intervenes in: (a) MPTP-induced DA neuron death in the SN
and (b) the neuroinflammatory process to which neurode-
generation associates. Therefore, we performed a confocal
study, combined with quantitative analysis, for MMP-9 im-
munopositive (MMP-9?) cell localization in control and
MPTP-treated mice. Brain sections were immunolabeled for
MMP-9 alone or in combination with different cell type-
specific markers: NeuN (neurons), TH (DA neurons), GSA
(microglia) and GFAP (astrocytes).
Before this, we carried out both gelatin zymography (on
SN and striatum tissue extracts) and in situ zymography
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(on brain sections), to verify the presence of MMP-9
activity in control and 72 h MPTP-treated mice (chosen as
a representative post-injection time point). Gelatin zy-
mography is a poorly sensitive and quite variable tech-
nique, and the signal we obtained from both SN and
striatum was too low to be properly quantified (see also
Lorenzl et al. 2004 on pools of entire midbrain extracts).
In situ zymography, instead, showed that in both brain
areas, MPTP treatment elicited an increase in cellular and
extracellular fluorescent signal when compared to control
(Fig. 2). Since the other gelatinase (gelatinase A, MMP-2),
differently from MMP-9, is scarcely detectable at the
protein level both before and after MPTP treatment
(unpublished observation), we hypothesized that most of
this labeling was generated by gelatinase B activation.
Confocal microscopy studies were performed on control
and MPTP-treated mice killed 24, 48, 72 h and 2 weeks
after the last toxin injection. Data will be presented sub-
divided by cell type (neuron, microglia, astrocytes).
MMP-9/NeuN/TH and MMP-9/NeuN co-localization
in the SNpc and striatum of control and MPTP-treated
mice
To ascertain whether MMP-9 was synthesized by DA
neurons in the SNpc and whether this expression changed
Fig. 1 MMP-9 mRNA and protein levels increase in both substantia
nigra (SN) and striatum after MPTP treatment. MMP-9 mRNA levels
in control and MPTP-treated mice. MMP-9 mRNA levels increase
significantly, compared to control (Cntr), within 24 h after the last
MPTP injection in both SN (a) and striatum (b). However, while in
the SN we observe a further increase after 48 h and then a decrease
towards Cntr levels, in the striatum MMP-9 mRNA decreases
significantly below Cntr, until the 2 weeks time point. n = 8 mice/
experimental group. Data are represented as the mean ± SEM. of
mRNA levels in MPTP-treated mice/control. c–d0 MMP-9 Western
immunoblot and relative quantitative analysis in control and MPTP-
treated mice. Typical MMP-9 Western immunoblot in the SN (c) and
striatum (d). MMP-9 antibody recognized two bands at the predicted
molecular mass of the pro- (100 kDa) and active (92 kDa) MMP-9.
The recombinant human MMP-9 used as standard (St) migrates at a
slightly lower molecular mass with respect to the mouse active MMP-
9. GAPDH was used as the internal reference protein. c0, d0
Densitometric analyses of the immunopositive bands reveal an early
and significant increase, compared to control, in the protein levels of
both pro- and active MMP-9, 24 h (SN) and 1 h (striatum) after
MPTP injection. Protein levels remain significantly higher than
control throughout the post-injection time considered. OD optical
density. n = 8 animals/experimental group. Data are represented as
the mean ± SEM of OD in MPTP-treated mice/control. *p B 0.05,
calculated by one-way ANOVA and Duncan’s test
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after MPTP administration, we performed a triple immu-
nofluorescence, by combining anti-MMP-9 with both
NeuN and TH immunolabeling. As shown in Fig. 3a,
MMP-9 largely co-localized with NeuN and TH, in both
control and Parkinsonian mouse brain sections, intensely
decorating cell bodies and axons. Extracellular dots of
immunoreactivity were also observed, likely representing
transversally cut axons and/or secreted MMP-9. Quantita-
tive analysis of the immunopositive cells showed that
numerous NeuN? cells expressed MMP-9 (Fig. 3a0).
Among these, a large part of TH? neurons were also MMP-
9? (Fig. 3a00), and the majority of NeuN? neurons were DA
(TH?) (Fig. 3a00), in both control and Parkinsonian mice.
As expected, MPTP-treatment determined a significant
decrease in MMP-9? cells within the following 24 h
(Fig. 3a0); this coincided with a significant decrease in the
total number of neurons (NeuN? in Fig. 3a0) and TH?
neurons (Fig. 3a00), both alone and in co-localization with
MMP-9, clearly noticeable also in the confocal images
(Fig. 3a). The number of all immunopositive cells (MMP-
9?, NeuN?, NeuN?/MMP-9?, TH? and TH?/MMP-9?)
partially, but significantly, recovered 2 weeks after MPTP
administration (Fig. 3a0, a00). This pattern was further ver-
ified in the second part of this work (conducted on MMP-9
KO mice) and confirmed by a parallel study, in which TH?
neurons, revealed by the immuno-enzymatic method of the
HRP-DAB, were counted in SNpc sections, serial to those
used in this study (Annese et al. 2013). Changes in TH
protein levels in the SN were also quantified by
Fig. 2 Gelatinolytic activity
increases in the SN and striatum
of MPTP-treated mice
compared to control.
Representative brain
cryosections showing an
increase, with respect to control,
in both number of labeled cells
and intensity of the fluorescent
signal of MMP-9 gelatinolyitc
activity after MPTP treatment,
obtained by in situ zimography.
Lines are to guide the eye in SN
demarcation. Scale bar 100 lm
cFig. 3 MMP-9 is mainly neuronal in both control and MPTP-treated
mice, but the number of immunopositive neurons is differently
modulated along the nigro-striatal pathway. Confocal images of
MMP-9 co-immunolabeling with NeuN and TH in the substantia
nigra pars compacta (SNpc) and striatum of control and MPTP-
treated mice (72 h after MPTP injection) and relative quantitative
analyses. a MMP-9 (green) co-localizes with both NeuN (purple) and
TH (red) in SNpc sections of control and parkinsonian mice. MMP-9
largely localizes in dopaminergic neurons, labeling both cell bodies
and axons (arrow in the merge panel). However, the few non-
dopaminergic neurons present in the SNpc are also immunopositive
(arrowhead in the merge panel). Nuclei are stained in blue with
DAPI. Scale bar 25 lm. a0 The number of MMP-9? (black bars),
NeuN? (gray bars) and NeuN?/MMP-9? (white bars) cells under-
goes a significant decrease, with respect to control (Cntr), 24 h after
MPTP treatment, followed by a partial, but significant recovery (with
respect to the 72 h time point) after 2 weeks. a00 The number of TH?
(black bars), TH?/MMP-9? (gray bars) cells follows the same time
course described for the SN. Differently, the number of NeuN?/TH-
(white bars) does not change and that of NeuN?/MMP-9?/TH-
(white–black bars) cells increases slightly, but significantly, 72 h after
MPTP treatment. b MMP-9 (green) largely co-localizes with NeuN
(purple) in sections of striatum from control and parkinsonian mice
(arrows in the enlarged boxed area), although not all neurons are
MMP-9? (arrowhead in the enlarged boxed area). Nuclei are stained
in blue with DAPI. Scale bar low magnification, 40 lm; enlarged
boxed area, 10 lm. b0 The number of MMP-9? cells (black bars)
increases significantly with respect to Cntr by 48 h after MPTP
injection, remaining higher up to 2 weeks. Differently, the number of
neurons, either expressing MMP-9 (NeuN?/MMP-9?) (white bars) or
not (NeuN?) (gray bars) does not change. n = 4 animals/experimen-
tal group. For all quantitative analyses, data are represented as the
mean ± SEM of the cell number/mm2. *p B 0.05 (MPTP vs. Cntr);
^p B 0.05 (2 weeks vs. 72 h MPTP) calculated by one-way ANOVA
and Duncan’s test
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densitometric analysis of Western immunoblot (Fig. 4a, a0)
and results were in accordance with what was shown by
immunohistochemistry.
From this quantitative study, it also emerged that the
number of non-DA neurons (NeuN?/TH-) remained stable
after MPTP treatment (Fig. 3a00), indicating that the toxin
does not affect this type of neurons in the SNpc. Moreover,
the number of non-DA neurons expressing MMP-9
(NeuN?/MMP-9?/TH-) increased slightly, but signifi-
cantly, 72 h after the last MPTP injection (Fig. 3a00), sug-
gesting that factors, possibly released by dying and/or
suffering DA neurons, as well as by other types of cells,
may trigger MMP-9 expression in the surrounding neurons.
Similar to the SNpc, MMP-9 immunolabeling in the
striatum largely co-localized with NeuN, although not all
neurons were MMP-9? and not all MMP-9?-cells were
neurons (Fig. 3b). Seventy-two hours after the last MPTP
injection, a clear increase in MMP-9 immunolabeling was
observed. Large part of the staining was visible outside the
cell bodies, being present not only in the extracellular
space, but also within the thin processes of non-neuronal
cells (see ahead in ‘‘Results’’), and into transversally cut
axons crossing the striatum (Fig. 3b). Quantitative analysis
showed that the number of MMP-9? cells increased sig-
nificantly, with respect to control, by 48 h after MPTP
injection, remaining higher than control up to 2 weeks after
(Fig. 3b0). Contrarily, the number of neurons, both positive
(NeuN?/MMP-9?) and negative (NeuN?) for MMP-9, did
not change after treatment, suggesting that the increase in
MMP-9? cells may depend on activated and/or newly
migrated non-neuronal cells.
Concomitant to confocal analysis, we evaluated TH
levels in the striatum of control and MPTP-treated mice by
Western immunoblot. Figure 4b, b0 shows that TH levels
significantly decreased with respect to control, 24 and 48 h
after MPTP treatment, being recovered in the following
time points but remaining below the control values. This is
in agreement with the results obtained by densitometric
evaluation of TH immunolabeling performed on striatum
sections adjacent to those utilized in this study (Annese
et al. 2013), as well as on sections from WT and MMP-9
KO mice (see ahead in ‘‘Results’’).
MMP-9/GSA co-localization in the SNpc and striatum
of control and MPTP-treated mice
Microglia, the brain immune resident cells, are main
modulators of neuroinflammation. As reported in the
Introduction, in both PD patients and MPTP animal models
of Parkinsonism, microglia shift from ‘‘surveillant’’ to
‘‘active’’, modify their morphology, and acquire migratory
and phagocyte capabilities, according to a well-described
step-to-step response (Streit et al. 1999). Here, we inves-
tigated whether MMP-9 was expressed by microglia and
Fig. 4 Time course of the changes in TH protein levels in both
substantia nigra (SN) and striatum of MPTP-treated mice. Typical
Western immunoblots revealing levels of TH on protein extracts from
the SN (a) and striatum (b) of control (Cntr) and MPTP-treated mice,
from 1 h to 2 weeks post-injection. The anti-TH antibody recognizes
a single band of about 62 kDa. The intensity of the band decreases
after MPTP treatment, with respect to Cntr, and partially recovers
after 2 weeks. GAPDH is used as the internal reference protein.
Molecular mass standards, expressed in kDa, are indicated on the
right hand side. a0, b0 Densitometric analysis reveals a significant
decrease in TH protein levels by 24 h (striatum)–48 h (SN), which
remain lower than control until the last time point examined.
However, a partial recovery, more evident in the SN, is observed after
2 weeks. OD optical density. n = 8 mice/experimental group. Data
are represented as the mean ± SEM of OD of the immunopositive
bands. *p B 0.05, calculated by one-way ANOVA and Duncan’s test
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whether this expression was modulated by acute MPTP-
treatment. For this purpose, we combined MMP-9 immu-
nolabeling with GSA staining, a classical marker for
microglia, widely used in the literature to identify both
resting and activated microglia (Streit and Kreutzberg
1987; Pott Godoy et al. 2008). The choice of GSA was
dictated by a technical impediment when combining MMP-
9 and microglia immunolabeling protocols using the clas-
sical Iba-1 or F4-80 antibodies. MPTP-induced microgli-
osis was, however, subsequently confirmed and quantified
in the following experiments conducted on WT and MMP-
9 KO mice (see ahead in ‘‘Results’’). For the MMP-9/GSA
analysis, we used a classical fluorescent microscope, as the
rhodamine labeling was rapidly fading under the confocal
beam. In both control SNpc and striatum, GSA staining
was scanty, mainly associated with blood vessels and small
cell processes (Fig. 5a, SNpc). The number of GSA? cells
significantly and progressively increased from 24 h to 72 h
after MPTP-treatment (Fig. 5a, a0, quantitative analysis)
and then significantly decreased (compared to the 72 h
time point) after 2 weeks, although remained higher than
control. In control mice, coexistence of GSA and MMP-9
(GSA?/MMP-9?) was rarely observed in both SNpc
(Fig. 5a0, quantitative analysis) and striatum (Fig. 5c,
quantitative analysis). By 24 h after MPTP treatment, the
number of GSA?/MMP-9? cells significantly increased in
both areas, with respect to control (SNpc: Fig. 5a0, quan-
titative analysis; striatum: Fig. 5c, quantitative analysis),
overlapping with the period of major loss of TH? neurons
in the SNpc and decrease in TH? fibers in the striatum.
Different from neurons, MMP-9 immunolabeling in GSA?
cells appeared in small discrete dots, possibly representing
points of accumulation/release. Two weeks later, while in
the SNpc the number of GSA?/MMP-9? cells returned to
control levels, concomitantly with the partial recovery of
TH? neurons, in the striatum it remained significantly
higher than control.
MMP-9/GFAP co-localization in the SNpc and striatum
of control and MPTP-injected mice
Since astrogliosis commonly follows microglia activation
in neuroinflammatory processes, we evaluated MMP-9
expression in astrocytes by co-localizing it with the cell-
specific marker GFAP. Confocal analysis showed that,
after MPTP treatment, both SNpc (Fig. 5b) and striatum
underwent prominent astrogliosis. The number of GFAP?
cells increased significantly after 24 h (Fig. 5b0, SNpc;
Fig. 5d, striatum), remaining higher than control up to
2 weeks. The number of astrocytes expressing MMP-9
(GFAP?/MMP-9?) increased with the same time course
than the number of GFAP? cells. As for microglia, the
number of double immunolabeled cells (Fig. 5b)
represented only a small percentage of the whole MMP-9?
cell population.
A summary of the changes in the percentage of the
different MMP-9? cell types, emerged from the confocal
and quantitative analyses, is shown in the pie charts of
Fig. 6. In control conditions, MMP-9 is mainly expressed
by neurons, in both SNpc and striatum. The number of
immunopositive glial cells increases significantly after
MPTP treatment, concomitantly with microgliosis and as-
trogliosis, and remains higher than control up to 2 weeks.
Sector indicated as ‘‘others’’ comprehend a category of
mixed cells, not identified in this study. A large part of
these cells are certainly represented by oligodendrocytes
(unpublished observation), which undergo massive oligo-
dendrogliosis (Annese et al. 2013). The rest could be
blood-born immune cells crossing the damaged blood brain
barrier, attracted by the inflammatory process; however,
their identity needs to be properly investigated.
MMP-9 immunolocalization and quantitative analysis
in control and parkinsonian macaques
The mouse model of Parkinsonism has the advantage of a
fast analysis of the cellular and molecular processes related
to the nigro-striatal pathway degeneration. On the other
hand, the use of the chronic macaque model of MPTP
administration is extremely important for a better under-
standing of the role of inflammatory processes in the long-
term disease progression, more similar to what happens in
humans. We had the opportunity to use sections of the
striatum (both caudate and putamen) of previously studied
macaques (Barcia et al. 2004, 2011). These samples were
already well characterized for the loss of DA neurons and
axons, as well as for microglia activation. Here, we eval-
uated MMP-9 expression, alone and in combination with
some of the specific markers used above (NeuN, GFAP), in
the striatum of both control and parkinsonian macaques
(2 years after MPTP-induced stable Parkinsonism). Similar
to mice, MMP-9 immunolabeling co-localized with the
neuronal marker NeuN (Fig. 7a), although numerous
MMP-9- neurons were also present. MPTP treatment
induced a clear up-regulation in MMP-9 immunolabeling
in both areas with respect to control (Fig. 7a). Quantitative
analysis confirmed a significant increase in both MMP-9?
cells and NeuN?/MMP-9? labeled neurons (Fig. 7a0). The
total number of NeuN? neurons, instead, remained com-
parable to control, suggesting that striatal neurons, previ-
ously immunonegative, were induced to express MMP-9 in
parkinsonian primates. Numerous MMP-9?/NeuN- cells,
with an apparent glial morphology and scarcely present in
control monkeys, were also observed (Fig. 7a).
GFAP immunolabeling showed a dramatic and persis-
tent astrogliosis in the striatum of MPTP-treated monkeys
Brain Struct Funct
123
when compared to control animals (Fig. 7b). Astrocyte
activation was characterized by an increase in cell size, as
well as in the number and length of cell processes
(Fig. 7b). GFAP/MMP-9 co-immunolabeling (MMP-9?/
GFAP?) showed that astroglia represented only a small
percentage of MMP-9? cells, in both control and parkin-
sonian monkeys. However, after MPTP treatment, the
number of MMP-9?/GFAP? cells increased significantly
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with respect to control (Fig. 7b0). For the same technical
reasons described for mice, we were unable to combine
MMP-9 staining with classical markers of microglial cells.
Evaluation of nigro-striatal pathway degeneration
and progression of neuroinflammation in MMP-9 KO
and wild-type mice
Based on the results obtained so far, the main question
remaining was related to whether MMP-9 could play a
primary role in MPTP-induced neuroinflammation and, as
a consequence, on SNpc DA neuron death. To unravel this
question, we acutely treated MMP-9 KO mice and their
matching WT with MPTP. Animals were killed 72 h and
2 weeks after MPTP administration, chosen as the most
representative dates in the neuroinflammatory response of
the nigro-striatal pathway. We performed HRP-DAB
immunohistochemistry for: (a) TH, to quantify DA neuron
death in the SNpc and the decrease in DA innervation in
the striatum; (b) Iba-1, to evaluate number and size of
microglia; (c) GFAP, to evaluate number and size of
astrocytes.
Quantification of TH-immunoreactivity in the SNpc
and striatum of wild-type and MMP-9 KO mice
after MPTP treatment
In both WT and MMP-9 KO mice, TH immunolabeling
in the SN revealed the characteristic distribution of DA
neurons in the pars compacta (Fig. 8a). However, the
number of DA neurons (TH?) in untreated MMP-9 KO
mice, was lower than in the WT, although this difference
was not significant (p = 0.18). Due to this initial dif-
ference, to clearly evaluate changes in DA neuron
number after MPTP treatment, we expressed this value
as the percentage compared to control. MPTP treatment
elicited significant loss of TH? neurons in the SNpc of
both genotypes 72 h after the last MPTP injection
(Fig. 8a, b, quantitative analysis). However, in MMP-9
KO mice, this reduction was significantly lower with
respect to control, with 54 % of TH? neurons left in the
wild-type mice versus 82 % in MMP-9 KO mice
(Fig. 8b). As expected, 2 weeks after MPTP treatment,
the percentage of TH? neurons increased in both geno-
types (Fig. 8a, b, quantitative analysis), being in MMP-9
KO mice not significantly different than in the control
mice (Fig. 8b). To further investigate this point, mid-
brain sections of control and MPTP-treated mice were
stained with cresyl violet and the total number of neu-
rons counted. The graph in Fig. 8c shows a significant
neuronal loss 72 h after MPTP injection, which does not
recover after 2 weeks. Moreover, the number of neurons
in MPTP-treated KO mice is always significantly higher
than that in the WT. This result definitely demonstrates
that, after MPTP treatment, not all SNpc neurons die,
but a number of affected neurons just stop synthesizing
and transporting TH along the axons, being able to
recover from toxic treatment.
In the striatum, TH immunolabeling (evaluated as OD
of gray scale units) was lower, although not significantly
(p = 0.44), in MMP-9 KO mice with respect to WT
(Fig. 8d, e, densitometric analysis), reasonably due to the
presence of a fewer number of DA neurons in the SNpc
of control mice. MPTP administration elicited a signifi-
cant decrease (72 h) and successive recovery (2 weeks vs.
72 h) in TH immunolabeling, although values remained
lower than controls (Fig. 8d, e, densitometric analysis).
Different from the SNpc, no significant differences were
bFig. 5 MMP-9 expression by microglia and astrocytes significantly
increase soon after MPTP treatment, concomitantly with a massive
inflammatory response. Confocal study of MMP-9 co-labeling with
GSA and GFAP in the substantia nigra pars compacta (SNpc) and
striatum of control and MPTP-treated mice and relative quantitative
analyses. a In the SNpc of control mice, GSA (red) staining labeled
microglia cell bodies and thin processes (arrowheads). MMP-9/GSA
co-localization is practically absent. Seventy-two hours after MPTP
treatment, an activated phenotype is recognizable, with increased cell
size. Labeling with MMP-9 (green) denotes some punctiform co-
localization (arrows and enlarged boxed area). Nuclei are counter-
stained with DAPI (blue). Scale bars 20 lm; enlarged boxed area,
25 lm. a0 Quantitative analysis shows that a very few of the MMP-9?
cells (black bars) are also GSA? (white bars), in both control (Cntr)
and MPTP-treated mice. However, while the number of MMP-9?
cells significantly decreases with respect to Cntr after MPTP
injection, that of GSA? (gray bars) and of GSA?/MMP-9? microglial
cells increases by 24 and 48 h, respectively. These values decrease
significantly, with respect to the 72 h time point, after 2 weeks.
b Representative confocal images of double-immunolabeling of
MMP-9 (green) and GFAP (red) in the SNpc of both control and
MPTP-treated animals. As for microglia, in control animals, astro-
cytes are little and dispersed (arrowheads). Seventy-two hours after
MPTP treatment, a prominent astrogliosis is evident, with increase in
cell size, number and length of cell processes. MMP-9 and GFAP co-
localized in part (arrows and enlarged boxed area). Nuclei are
counterstained with DAPI (blue). Scale bars 20 lm; enlarged boxed
area, 25 lm. b0 Quantitative analysis of GFAP? (gray bars) and
GFAP?/MMP-9? cells (white bars) show a significant increase in the
number of labeled cells by 24 h after MPTP treatment with respect to
Cntr. Both values decrease significantly at the end of the post-
operative time considered, when the GFAP? cell number returns
similar to Cntr. Quantitative analysis of MMP-9? cells alone (black
bars) or in co-localization with GSA (white bars in c) and GFAP
(white bars in d) in the striatum. MMP-9? cells increase significantly,
with respect to control, after MPTP treatment, remaining high up to
the 2 weeks time point. Also the number of both microglia (GSA?
cells, gray bars in c) and astrocytes (GFAP? cells, gray bars in d),
increases. After 2 weeks, GSA? cells and GFAP?/MMP-9? cells
decrease significantly with respect to the previous time point, while
the number of GSA?/MMP-9? and GFAP? cells remains similar. For
all quantitative analyses, n = 4 animals/experimental group. Data are
represented as the mean ± SEM of the cell number/mm2. *p B 0.05
(MPTP vs. Cntr), ^p B 0.05 (2 weeks vs. 72 h MPTP) calculated by
one-way ANOVA and Duncan’s test
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observed in the striatum between WT and MMP-9 KO
mice at both 72 h and 2 weeks after MPTP treatment,
although the recovery of TH immunolabeling in the KO
mice was more significant (p \ 0.05, when evaluated by
the Student’s t test) than in the WT. Once more, these
data suggest that lack of MMP-9 protects DA neurons
from death, reflected also in a higher degree of striatal
DA reinnervation.
Quantification of Iba-1-immunopositive (Iba-1?) cells
in the SNpc and striatum of wild-type and MMP-9 KO mice
after MPTP treatment
We performed immunolabeling on brain sections, adjacent
to those immunoreacted for TH, with an antibody directed
against Iba-1, a microglia cell-specific protein, which
labels both resting and active microglia. Figure 9a shows
Iba-1 immunoreactivity in the SN of control and MPTP-
treated mice. Differences in the overall intensity of im-
munolabeling between experimental groups can be appre-
ciated, as well as the appearance of large and intensely
Fig. 6 Pie charts resuming the
changes in the number of the
different cell types expressing
MMP-9 in the mouse SNpc and
striatum. MMP-9 is mainly
expressed by neurons in both
SNpc (left column) and striatum
(right column). The percentage
of MMP-9? neurons decreases
significantly after MPTP
treatment, in coincidence with
dopaminergic neuron loss and
neuroinflammation (24–72 h),
whereas that of MMP-9?
microglia, astrocytes and other
types of cells increases.
Two weeks after MPTP
treatment, percentages return
similar to control
cFig. 7 MMP-9 expression in neurons and astrocytes significantly
increases in the caudate and putamen of parkinsonian Macaca
fascicularis, coinciding with a chronic and massive neuroinflamma-
tion. Confocal study of MMP-9 co-immunolabeling with NeuN and
GFAP in the caudate and putamen of control and MPTP-treated
monkeys and relative quantitative analyses. a MMP-9 immunofluo-
rescence (green) decorates the cell bodies of numerous cells, mainly
with a glial morphology. Co-localization of MMP-9 and NeuN
(purple) (arrows and enlarged boxed areas) increases after 2 years of
stable Parkinsonism. Nuclei are counterstained with DAPI (blue).
Scale bars 25 lm. a0 Quantitative analysis of MMP-9? (black bars),
NeuN? (gray bars) and NeuN?/MMP-9? (white bars) cells indicates
a significant increase, with respect to control (Cntr), in the number of
cells expressing MMP-9, including neurons, after induction of stable
parkinsonism in both caudate and putamen. Differently, the number
of striatal neurons remains unchanged. b Co-immunolabeling of
MMP-9 (green) and GFAP (red) shows a clear astrogliosis after
MPTP treatment. A number of cells and processes are immunolabeled
with both markers (arrows and enlarged boxed areas). Nuclei are
stained with DAPI (blue). Scale bars 25 lm. b0 Quantitative analysis
of MMP-9? (black bars), GFAP? (gray bars) and GFAP?/MMP-9?
(white bars) cells show a significant increase, with respect to control,
in the number of astrocytes, expressing or not MMP-9, in both
caudate and putamen. n = 3 monkeys (control) and 5 monkeys
(Parkinsonian). For all quantitative analyses, data are represented as
the mean ± SEM of cell number/mm2. *p B 0.05, **p B 0.01,
***p B 0.001 calculated by the Student’s t test
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labeled Iba-1? cells 72 h after MPTP treatment in both WT
and MMP-9 KO mice. Details of microglial cells in WT
(Fig. 9a1, control; Fig. 9a2, 72 h MPTP) and MMP-9-KO
(Fig. 9a3, control; Fig. 9a4, 72 h MPTP) mice clearly show
an increase in cell size and in the amount of processes after
MPTP treatment with respect to untreated controls, in both
genotypes. However, changes in WT mice are more pro-
nounced than in MMP-9 KO mice. These differences were
confirmed by quantitative analysis, in which we evaluated
mean cell number/area, mean area/cell and total area
occupied by all Iba1? cells. The number of microglial cells
increased significantly 72 h after MPTP treatment, and
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began to decline by 2 weeks compared to the 72 h time
point, although remaining higher than control (Fig. 9b).
We did not observe differences in cell numbers between
the two genotypes, in both control and MPTP-treated mice,
meaning that the absence of MMP-9 does not affect
microglia cell generation, division and recruitment to the
site of damage. Both mean cell area (Fig. 9c) and total
area/field occupied by Iba1? cells (not shown) changed
according to cell number. However, 72 h after treatment,
when microglia activation is at its maximum, these values
were significantly lower in MMP-9 KO mice with respect
to WT mice.
In the striatum, results were comparable to those in the
SNpc. Figure 9d is representative of Iba-1 immunolabeling
in the different experimental groups. Insets into the figures
highlight the morphological characteristics of individual
cells, in which differences in cell size between WT and
MMP-9 KO mice after MPTP treatment can be appreci-
ated. Statistical analyses relative to Iba-1? cell number
(Fig. 9e), mean cell area (Fig. 9f), and total area/field
occupied by Iba1? cells (not shown) are in accordance with
the statistics in the SNpc. As a notable exception, 2 weeks
after MPTP treatment, mean cell size remains higher in
WT animals compared to untreated controls, suggesting a
prolongation of the inflammatory reaction with respect to
what happens in the SN.
Quantification of GFAP-immunopositive (GFAP?) cells
in the SNpc and striatum of wild-type and MMP-9 KO mice
after MPTP treatment
Figure 10a shows GFAP immunolabeling in sections of the
SN from control and MPTP-treated WT and MMP-9 KO
mice. Intensity and distribution of the immunostaining
increased 72 h after MPTP injection with respect to con-
trol, decreasing again after 2 weeks. Astrocyte morpho-
logical changes after MPTP treatment in WT (Fig. 10a1,
control; Fig. 10a2, 72 h MPTP) and MMP-9-KO
(Fig. 10a3, control; Fig. 10a4, 72 h MPTP) mice are
shown. Quantitative analysis of the changes in GFAP? cell
number (Fig. 10b), mean cell size (Fig. 10c), and total
area/photographic field occupied by GFAP? cells (not
shown) was fairly similar to what was previously described
for microglia: i.e. all parameters increased 72 h after
MPTP treatment and began to decline within 2 weeks.
Similar to microglia, 72 h after MPTP administration, the
absence of active MMP-9 did not produce differences
between the two genotypes in terms of astrocyte cell
numbers (Fig. 10b), but only in cell size (Fig. 10c).
In the striatum, results were comparable to those in the
SNpc. Figure 10d shows GFAP immunolabeling in control
WT and MMP-9 KO mice and the changes after MPTP
treatment (details of single astrocytes for each experi-
mental group are shown in the inset of figures). Quantita-
tive analyses are reported in Fig. 10e (GFAP? cell number)
and Fig. 10f (mean cell area).
Data collected from the experiments on WT and MMP-9
KO mice were compared to each other in a correlation
study. A significant inverse correlation between cell num-
ber and size (mean and total area) of both Iba-1? and
GFAP? cells and a decrease in TH? cell number and TH?
fibers in the SNpc and striatum, respectively, were
observed (Fig. 11).
Discussion
Neuroinflammation is a feature of PD common to several
brain pathologies. Its cellular and molecular aspects have,
therefore, become a major field of investigation as a uni-
fying ground on the causative and/or aggravating element
of neurodegenerative diseases. Animal models of Parkin-
sonism, as those adopted in this study, allow the identifi-
cation of the temporal and cellular basis of
neuroinflammation, its correlation with the primary
degeneration of DA nigro-striatal pathway and the molec-
ular signals involved.
bFig. 8 After MPTP treatment, the amount of dopaminergic neurons
and fibers in the substantia nigra pars compacta (SNpc) and striatum
is significantly higher in MMP-9 KO mice with respect to wild-type.
a TH immunohistochemistry in the SNpc of both wild-type and
MMP-9 KO mice shows a decrease (72 h) of the immunolabeling
after MPTP treatment with respect to control. This reduction partially
recovers after 2 weeks from the treatment. Scale bar 400 lm.
b Quantitative analysis of the number of TH? cells (expressed as
the percentage with respect to their own control) confirms this pattern
and shows that the number of dopaminergic neurons expressing TH is
always significantly higher in the KO genotype (black bars) with
respect to wild-type (white bars). Partial, but significant, retrieval of
TH? neurons at the 2 weeks time point indicates that a number of
dopaminergic neurons survive MPTP intoxication and recover their
functionality. c Quantitative analysis of the changes of SNpc neurons,
stained with the histological dye cresyl violet, was performed to
ascertain neuronal loss with respect to TH-expressing neurons. Data
demonstrate effective and definitive loss of a percentage of neurons
after MPTP treatment in both genotypes (without recovery after
2 weeks). The number of lost neurons was always significantly higher
in wild-type mice (white bars) with respect to MMP-9 KO (black
bars). d As for the SNpc, TH immunostaining of striatal sections
shows an evident decrease (72 h) and successive partial recovery
(2 weeks) of immunolabeling after MPTP treatment with respect to
control, in both wild-type and MMP-9 KO mice. Scale bar 1 mm.
e Densitometric analysis of the immunopositive signal confirms a
significant drastic decrease in TH immunolabeling 72 h after MPTP
treatment and a significant recovery after 2 weeks. n = 5 mice (wild-
type) and 8 mice (MMP-9 KO). For all quantitative analyses, data are
represented as the mean ± SEM of the number of neurons (b, c) and
of the OD in MPTP-treated mice/control (e). *p B 0.05,
***p B 0.001 (MPTP vs. Cntr), #p B 0.05, ###p B 0.001 (MMP-9
KO vs. wild-type mice), ^p B 0.05, ^^^p B 0.001 (2 weeks vs. 72 h
MPTP), calculated by the Student’s t test
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After MPTP intoxication, microglia is early recruited,
followed by T-cell infiltration and astrogliosis when neu-
ronal loss has already progressed (Hirsch and Hunot 2009).
Perpetuation of microgliosis can, therefore, be a crucial
non-turning point for neuron degeneration. After a harmful
event, reactive microglia is involved in scavenging neu-
ronal debris; however, an adverse role emerges when pro-
inflammatory cytokines (i.e. INT-c; TNF-a) perpetuate
inflammation, favoring neurodegeneration (Barcia et al.
2005, 2011; Pott Godoy et al. 2008). In this study, MPTP-
treated mice develop a prominent but transient inflamma-
tion, which coincides with DA neuron and fiber degener-
ation; successive remission of this inflammation correlates
with functional recovery of surviving neurons. By com-
bining TH immunohistochemistry and cresyl violet stain-
ing, we confirmed that part of the DA neurons in the
lesioned SNpc may be only temporarily affected, remain-
ing functionally silent for a short time and with great
potentiality to survive intoxication and to partially rein-
nervate the striatum, as previously reported in both MPTP-
treated mice and monkeys (Bezard et al. 2000; Mounayar
et al. 2007). Although the observations in mice are dif-
ferent than the irreversible degeneration that MPTP pro-
vokes in humans (Langston et al. 1983) and monkeys
(Barcia et al. 2004), these results pose a new ground for
studies aimed at uncovering molecular mechanisms
promoting rescue of affected neurons and re-establishing
nigro-striatal connections.
The major point of this study was to identify factors
responsible for the perpetuation of glia proliferation and/or
activation, which shifts a beneficial response, intended to
maintain brain homeostasis, into a deadly chronic state. A
role could be played by MMPs, involved in several CNS
injuries and diseases, but at the same time promoters of
neuro-reparative and physiological processes (Yong 2005;
Zhang et al. 2010; De Stefano et al. 2012). MMPs detri-
mental role relies on the unbalance of the delicate equi-
librium between activation and inhibition; therefore, re-
establishment of this equilibrium could be a therapeutic
strategy aimed at modulating neuroinflammation.
Related to Parkinsonism, in vitro studies have demon-
strated intracellular activation of MMP-3 after neuronal
stress, with consequent induction of apoptotic-signaling
cascades (Choi et al. 2008; Kim et al. 2010). MMP-3
released by dying neurons activates microglia, further
contributing to neurodegeneration (Kim et al. 2007) along
with MMP-9 (Woo et al. 2008). Altered gelatinase
expression in the SN of post-mortem brains of PD patients
was first reported by Lorenzl et al. (2002), according to
whom no alteration in MMP-9 protein and activity levels
were observed compared to age-matched controls. Later
on, the same authors reported an increase in MMP-9
mRNA, protein, and activity levels in the SN and striatum
of pools of MPTP-treated mice (Lorenzl et al. 2004),
although these data were not detailed in terms of post-
injection times, and lacked a proper quantitative/qualitative
evaluation of the type/s of cells in which MMP-9 expres-
sion was modulated. According to our data, MMP-9 indeed
turns out to be highly expressed and modulated in mouse
SNpc and striatum from the very first stages of MPTP-
induced neuroinflammation, and throughout the 2 weeks
period of observation. Qualitative and quantitative data,
obtained by co-immunolabeling MMP-9 with different
cell-specific markers, show significant enhancement of
MMP-9 expression in reactive microglia and astrocytes
recruited in SNpc and striatum. This is in accord to the
literature, where it is reported that neurons, microglia and
astrocytes synthesize both gelatinases (MMP-2 and MMP-
9), although MMP-9 is the only highly modulated under
experimental conditions (Yong 2005; Wilczynski et al.
2008; Candelario-Jalil et al. 2009; Walker and Rosenberg
2010). In MPTP-injected mice, neuroinflammation is
transient and starts decreasing within 2 weeks after the
treatment, when the number of MMP-9? microglia and
astrocytes in the nigro-striatal pathway declines to control
levels. This overlaps the partial recovery of TH protein
levels and TH? neurons and fibers (Annese et al. 2013; this
study), suggesting that glial MMP-9 is a major player in the
bFig. 9 MPTP treatment induces a prominent microgliosis in the
substantia nigra pars compacta (SNpc) and striatum of both wild-type
and MMP-9 KO mice, but the mean cell size is significantly reduced
in the KO genotype. a, d Iba-1 immunohistochemistry in the SNpc
(a) and striatum (d) of both wild-type and MMP-9 KO mice shows an
increase, with respect to control, in the amount of clusters of reactive
microglia 72 h after MPTP treatment. After 2 weeks, number and size
of microglial cells begin to reduce with respect to the 72 h post-
injection time. Insets show details of microglia morphology, before
and after MPTP treatment. Insets in panel a (SNpc): a1, a3 are
enlargements of microglial cells in control wild-type and MMP-9 KO
mice, respectively; a2, a4 are enlargements of microglial cells 72 h
after MPTP treatment of wild-type and MMP-9 KO mice, respec-
tively. Scale bars a, 400 lm; d, 200 lm; insets 20 lm. b, e Quan-
titative analysis on Iba-1? cells in the SNpc and striatum of wild-type
and MMP-9 KO mice shows that the number of microglial cells
increases significantly 72 h after MPTP treatment and begins to
decrease after 2 weeks, although remaining higher than control
(Cntr). No differences are observed between the two genotypes. Data
are represented as the mean ± SEM of the cell number/photographic
field. c, f Quantitative analysis on Iba-1? cells in the SNpc and
striatum of wild-type and MMP-9 KO mice shows that the mean area
occupied by each microglial cell significantly increases 72 h after
MPTP treatment, with respect to Cntr, and then decreases after
2 weeks. However, in MMP-9 KO mice, this parameter is signifi-
cantly lower compared to wild-type, at least after 72 h. n = 5 mice
(wild-type) and 8 mice (MMP-9 KO). For all quantitative analyses,
data are represented as the mean ± SEM of cell area (lm2);
*p B 0.05, **p B 0.01, ***p B 0.001 (MPTP vs. Ctrl); ^p B 0.05,
^^^p B 0.001 (2 weeks vs. 72 h MPTP); #p B 0.05, ##p B 0.01
(MMP-9 KO vs. wild-type), calculated by the Student’s t test
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ignition of neuroinflammation. Specifically, based on the
results obtained in KO mice, MMP-9 appears to be
important for glia ‘‘activation’’, but not proliferation. In
fact, 72 h after MPTP treatment, while the number of
microglia and astrocytes in both SNpc and striatum of WT
and MMP-9 KO mice are similar, mean cell size and the
total area that reactive glia occupies per section are sig-
nificantly higher in WT mice. This difference disappears
after 2 weeks, when inflammation is subsiding. In the
striatum, both the number of MMP-9? glial cells and TH
protein levels decline slower than in the SNpc, possibly
related to its complex circuitry. Striatal response to MPTP
is prompt, as the toxin first affects SNpc neuron activity
and viability (Herkenham et al. 1991), with consequent
striatal neuronal denervation and retrograde reaction of
cortical neurons, which also project to the striatum, exac-
erbating and prolonging the inflammatory process.
Data on MMP-9 KO mice indicate that inflammatory
glia hampers neuron survival, as a reduction in reactive glia
with respect to WT correlates with a higher number of TH?
neurons (functional DA neurons) and cresyl violet-stained
neurons (effective number of neurons) in the SNpc, at both
72 h and 2 weeks post-treatment. We do not exclude that
MMP-9, early released by affected DA neurons, may
contribute to neuronal death by disrupting cell–cell and
cell-ECM linkage (Kim et al. 2009).
A role of MMP-9 in the exacerbation of inflammation is
also suggested by the results on parkinsonian macaques,
where MPTP-induced long-lasting neuroinflammation
correlates with progressive degeneration of nigro-striatal
circuitry. The numbers of MMP-9? striatal neurons and
astrocytes increase when compared to control, suggesting
that molecular signals released by ‘‘denervated’’ neurons
and axons support the inflammatory environment. MMP-9
could be a good candidate, as can favor migration of glial
cells by cleaving/modifying cell surface receptors, acti-
vating chemotactic factors and pro-inflammatory chemo-
kines (IL-1b, TNF-a) (Kawasaki et al. 2008), and
degrading ECM proteins. On the other hand, TNF-a and
IL-1 b induce a prominent release of MMP-9 by glial cells
(Kauppinen and Swanson 2005), which in turn amplify
their reactive state (Sbai et al. 2010), further modifying cell
size and enhancing amoeboid movements (Fig. 12).
MMP activity can switch from harmful to reparative,
allowing axon re-growth, remyelination and re-establish-
ment of connectivity (Yong 2005; Agrawal et al. 2008,
Huntley 2012; De Stefano et al. 2012). In particular, oli-
godendrocyte-derived MMP-9 supports oligodendrogliosis
and myelin restoration (Uhm et al. 1998; Oh et al. 1999;
Larsen et al. 2003). We previously demonstrated that
MPTP treatment of both mice and monkeys induces a
prominent oligodendrogliosis concomitant to the inflam-
matory process here described (Annese et al. 2013). In this
study, a number of cells classified as ‘‘others’’, among
which there are oligodendrocytes (unpublished observa-
tion), express MMP-9, both before and after MPTP treat-
ment. Therefore, we hypothesize that, in parkinsonian
mice, persistent expression of active MMP-9 may be
implicated in late reparative processes by: mediating oli-
godendrogliosis, which implies myelin digestion and cell
remodeling; favoring elongation and sprouting of regen-
erating axon once released by growth cones, by remodeling
ECM proteins; supporting formation of new myelin sheaths
and oligodendrocyte-axon connections (Larsen et al. 2003,
2006). These events have been summarized in the cartoon
depicted in Fig. 12, which takes into account both previous
(Annese et al. 2013) and present results for a more com-
prehensive picture.
Results obtained in MPTP-treated macaques differ,
but do not contradict, those described in mice. Two
years after establishment of stable Parkinsonism, in the
monkey striatum both inflammation (this study; Barcia
et al. 2004, 2011) and oligodendrogliosis (Annese et al.
2013) are significantly higher than in control animals.
Differences inter species (macaque vs. mouse) and/or
MPTP administration modality (chronic vs. acute)
determine pathological traits more similar in the maca-
que to human PD. Therefore, neuronal damage initiates a
cascade of glia-derived and auto-perpetuating
bFig. 10 MPTP treatment induces a prominent astrogliosis in the
substantia nigra pars compacta (SNpc) and striatum of both wild-type
and MMP-9 KO mice, but the mean cell size is significantly reduced
in the KO genotype. GFAP immunohistochemistry in the SNpc
(a) and striatum (d) of both wild-type and MMP-9 KO mice shows an
increase, with respect to control, in the amount of reactive astrocytes
72 h after MPTP treatment. Reactive astrocytes increase cell size and
complexity of their processes. After 2 weeks, astrocyte number and
size begin to reduce with respect to the 72 h post-injection time.
Insets show details of astrocyte morphology, before and after MPTP
treatment. Insets to panel a (SNpc): a1 and a3 are enlargements of
astrocytes in control wild-type and MMP-9 KO mice, respectively; a2
and a4 are enlargements of astrocytes 72 h after MPTP treatment of
wild-type and MMP-9 KO mice, respectively. Scale bars a, 400 lm;
d, 200 lm; insets, 20 lm. b, e Quantitative analysis on GFAP? cells
in the SNpc and striatum of wild-type and MMP-9 KO mice shows
that the number of astrocytes increases significantly 72 h after MPTP
treatment and begin to decrease after 2 weeks, although remaining
higher than control (Cntr). No differences are observed between the
two genotypes. Data are represented as the mean ± SEM of the cell
number/photographic field. c, f Quantitative analysis on GFAP? cells
in the SNpc and striatum of wild-type and MMP-9 KO mice shows
that the mean area occupied by each astrocyte significantly increases
72 h after MPTP treatment, with respect to Cntr, and then decreases
after 2 weeks. However, 72 h after MPTP treatment, this parameter in
MMP-9 KO mice is significantly lower compared to wild-type. n = 5
mice (wild-type) and 8 mice (MMP-9 KO). For all quantitative
analyses, data are represented as the mean ± SEM of cell area (lm2);
**p B 0.01, ***p B 0.001 (MPTP vs. Ctrl); ^^^p B 0.001 (2 weeks
vs. 72 h MPTP); #p B 0.05 (MMP-9 KO vs. wild-type), calculated by
the Student’s t test
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inflammatory signals, which favor progressive DA neu-
ron loss (Brochard et al. 2009), and promote formation
of a glial scar. This would impose a barrier to axon
regeneration (Rolls et al. 2009) and create a hostile
environment, in which oligodendrocyte activity becomes
ineffective (Goldschmidt et al. 2009).
Fig. 11 Glial cells activation
(neuroinflammation) inversely
correlates with the number of
TH? cells in the substantia nigra
(SN) and levels of TH
immunopositivity in the
striatum. Increase in the mean
cell area (lm2) occupied by
both microglia (Iba-1? cells)
and astrocytes (GFAP? cells)
inversely correlates to the levels
of TH immunostaining in both
SNpc and striatum of wild-type
mice (black dots and black
tendency lines). The inverse
correlation is almost lost in the
MMP-9 KO mice (red dots and
red tendency lines). n = 15
mice (wild-type) and 24 mice
(MMP-9 KO). p values,
calculated by Pearson
correlation coefficient (R2), are
indicated for each graph
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In conclusion, MMP-9 could be a possible therapeutic target
for the treatment of acute neuroinflammation in Parkinsonism.
However, MMP roles in physiological and reparative pro-
cesses, and the perfect timing at which beneficial effects can
revert into detrimental, complicate the efforts of treatment with
MMP inhibitors. Therefore, models reproducing develop-
mental stages of the disease are useful to clarify time and place
of MMP activation to devise therapeutic strategies.
Fig. 12 Synopsis of the
response of the nigro-striatal-
cortical circuit to acute MPTP
intoxication. In the dynamics of
the events, the proposed role of
MMP-9 in the exacerbation of
dopaminergic neuron death and
neuroinflammatory response is
highlighted. Oligodendrocytes
and the hypothesized role they
may play in the process of
partial recovery of the nigro-
striatal pathway are also
depicted
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